PMID- 34123866
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20230920
IS  - 2235-2988 (Electronic)
IS  - 2235-2988 (Linking)
VI  - 11
DP  - 2021
TI  - Deciphering Human Leukocyte Antigen Susceptibility Maps From Immunopeptidomics 
      Characterization in Oncology and Infections.
PG  - 642583
LID - 10.3389/fcimb.2021.642583 [doi]
LID - 642583
AB  - Genetic variability across the three major histocompatibility complex (MHC) class 
      I genes (human leukocyte antigen [HLA] A, B, and C) may affect susceptibility to 
      many diseases such as cancer, auto-immune or infectious diseases. Individual 
      genetic variation may help to explain different immune responses to 
      microorganisms across a population. HLA typing can be fast and inexpensive; 
      however, deciphering peptides loaded on MHC-I and II which are presented to T 
      cells, require the design and development of high-sensitivity methodological 
      approaches and subsequently databases. Hence, these novel strategies and 
      databases could help in the generation of vaccines using these potential 
      immunogenic peptides and in identifying high-risk HLA types to be prioritized for 
      vaccination programs. Herein, the recent developments and approaches, in this 
      field, focusing on the identification of immunogenic peptides have been reviewed 
      and the next steps to promote their translation into biomedical and clinical 
      practice are discussed.
CI  - Copyright (c) 2021 Juanes-Velasco, Landeira-Vinuela, Acebes-Fernandez, Hernandez, 
      Garcia-Vaquero, Arias-Hidalgo, Bareke, Montalvillo, Gongora and Fuentes.
FAU - Juanes-Velasco, Pablo
AU  - Juanes-Velasco P
AD  - Department of Medicine and Cytometry General Service-Nucleus, CIBERONC, Cancer 
      Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.
FAU - Landeira-Vinuela, Alicia
AU  - Landeira-Vinuela A
AD  - Department of Medicine and Cytometry General Service-Nucleus, CIBERONC, Cancer 
      Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.
FAU - Acebes-Fernandez, Vanessa
AU  - Acebes-Fernandez V
AD  - Department of Medicine and Cytometry General Service-Nucleus, CIBERONC, Cancer 
      Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.
FAU - Hernandez, Angela-Patricia
AU  - Hernandez AP
AD  - Department of Medicine and Cytometry General Service-Nucleus, CIBERONC, Cancer 
      Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.
FAU - Garcia-Vaquero, Marina L
AU  - Garcia-Vaquero ML
AD  - Department of Medicine and Cytometry General Service-Nucleus, CIBERONC, Cancer 
      Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.
FAU - Arias-Hidalgo, Carlota
AU  - Arias-Hidalgo C
AD  - Department of Medicine and Cytometry General Service-Nucleus, CIBERONC, Cancer 
      Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.
FAU - Bareke, Halin
AU  - Bareke H
AD  - Department of Medicine and Cytometry General Service-Nucleus, CIBERONC, Cancer 
      Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.
FAU - Montalvillo, Enrique
AU  - Montalvillo E
AD  - Department of Medicine and Cytometry General Service-Nucleus, CIBERONC, Cancer 
      Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.
FAU - Gongora, Rafael
AU  - Gongora R
AD  - Department of Medicine and Cytometry General Service-Nucleus, CIBERONC, Cancer 
      Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.
FAU - Fuentes, Manuel
AU  - Fuentes M
AD  - Department of Medicine and Cytometry General Service-Nucleus, CIBERONC, Cancer 
      Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, Spain.
AD  - Proteomics Unit, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), Salamanca, 
      Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210528
PL  - Switzerland
TA  - Front Cell Infect Microbiol
JT  - Frontiers in cellular and infection microbiology
JID - 101585359
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Peptides)
SB  - IM
MH  - HLA Antigens
MH  - *Histocompatibility Antigens Class I
MH  - *Histocompatibility Antigens Class II
MH  - Humans
MH  - Peptides
MH  - T-Lymphocytes
PMC - PMC8195621
OTO - NOTNLM
OT  - human leukocyte antigen
OT  - immunochromatography
OT  - immunopeptidomics
OT  - proteomics
OT  - vaccines
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/06/15 06:00
MHDA- 2021/07/06 06:00
PMCR- 2021/05/28
CRDT- 2021/06/14 09:50
PHST- 2020/12/16 00:00 [received]
PHST- 2021/04/29 00:00 [accepted]
PHST- 2021/06/14 09:50 [entrez]
PHST- 2021/06/15 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2021/05/28 00:00 [pmc-release]
AID - 10.3389/fcimb.2021.642583 [doi]
PST - epublish
SO  - Front Cell Infect Microbiol. 2021 May 28;11:642583. doi: 
      10.3389/fcimb.2021.642583. eCollection 2021.